The World Health Organization (WHO) as well as public health officials in Australia, Canada, Europe, and the United States recommend vaccination of young women against HPV to prevent cervical cancer, and to reduce the number of treatments for cervical cancer precursors. The death rate from cervical cancer in the United States is 3 per 100,000 and in 2011, about 12,000 women were diagnosed with cervical cancer and 4,000 died. In 2009, there were about 34,000 deaths from car accidents in the U.S. for a death rate of 11 per 100,000. HPV infection is extremely common; most sexually active people will be infected with HPV at some point in life. HPV infection usually causes no symptoms, but can cause genital warts and anal cancer in both women and men. The HPV vaccine prevents infection by the HPV types responsible for most cervical cancers. There are two available forms of the HPV vaccine: Cervarix; prevents infection by HPV-16 and HPV-18 and Gardasil; prevents infection by HPV-16, HPV-18, and also HPV-6 and HPV-11. There are many side events may caused by HPV vaccines such as; seizures, fatigue, strokes, dizziness, weakness, headaches, stomach pains, vomiting, muscle pain and weakness, joint pain, auto-immune problems, chest pains, hair loss, appetite loss, shortness of breath, heart problems, personality changes, insomnia, hand/leg tremors, arm/leg weakness, paralysis, itching, rashes, swelling, aching muscles, pelvic pain, nerve pain, menstrual cycle changes, fainting, swollen lymph nodes, night sweats, nausea, temporary vision/hearing loss. This topic review focused mainly on the side effects and health serious problems with Gardasil vaccine.
Key words: HPV vaccine; Cervical cancer; Cervarix; Gardasil
Copyright © 2014 by The American Society for BioMedicine and BM-Publisher, Inc.
- Cervantes J, Lema C, Hurtado L, Andrade R, Quiroga G, Garcia G, et al. Prevalence of human papillomavirus infection in rural villages of the Bolivian Amazon. Rev Inst Med Trop São Paulo. 2003;45(3):131–135.
- Donegan K, Beau-Lejdstrom R, King B, Seabroke S, Thomson A, Bryan P. Bivalent human papillomavirus vaccine and the risk of fatigue syndromes in girls in the UK. Vaccine. 2013;31(43):4961–4967.
- FUTURE II study group Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356:1915–1927.
- Tanaka H, Fujita Y, Takenaka Y, et al. Japanese clinical guidelines for juvenile orthostatic dysregulation version 1. Pediatr Int. 2009;51:169–179.
- Okubo S. Digital plethysmogram. In: Kanai M, editor. Manual of clinical and laboratory medicine. 31. Tokyo: Kanehara Publishing Inc.; 1998. pp. 1546–1547.
- Bruehl S, Harden RN, Galer BS, et al. Extensive validation of IASP diagnostic criteria for complex regional pain syndrome and proposed research diagnostic criteria. Pain. 1999;81:147–154.
- Shoenfeld Y, Agmon-Levin N. ASIA-autoimmune/inflammatory syndrome induced by adjuvants. J Autoimmun. 2011;36:4-8.
- Gisselquist DP. Estimating HIV-1 transmission efficiency through unsafe medical injections. Int J STD AIDS. 2002;13:152–159.
- Wilder RT. Management of pediatric patients with complex regional pain syndrome. Clin J Pain. 2006;22:443–448.
- Cervantes J, Lema C, Hurtado L, et al. Prevalence of human papillomavirus infection in rural villages of the Bolivian Amazon. Rev Inst Med Trop São Paulo. 2003;45(3):131–135.
- Cervantes JL. Multiple human papillomavirus infection: don't forget the genetic background. J Infect Dis. 2011;204(11):1816–1817.
- Goldenberg DL. Diagnosis and differential diagnosis of fibromyalgia. Am J Med. 2009;122(Suppl. 12):S14-S21.
- Moro PL, Zheteyeva Y, Lewis P, et al. Safety of quadrivalent human papillomavirus vaccine (Gardasil) in pregnancy: adverse events among non-manufacturer reports in the Vaccine Adverse Event Reporting System 2006-2013. Vaccine. 2015;33(4):519–522.
- Soldevilla HF, Briones SF, Navarra SV. Systemic lupus erythematosus following HPV immunization or infection? Lupus. 2012;21(2):158–161.
- Richards S, Chalkiadis, Lakshman R, Buttery JP, Crawford N.W. Complex regional pain syndrome following immunization. Arch. Dis. Child. 2012;97:913–915.
- Corona Gutierrez CM, Tinoco A, Navarro T, et al. Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus. Hum Gene Ther 2004;15:421-31
- Trimble CL, Peng S, Thoburn C, Kos F, Wu TC. Naturally occurring systemic immune responses to HPV antigens do not predict regression of CIN2/3. Cancer Immunol Immunother 2010;59:799-803.
- Steele JC, Mann CH, Rookes S, Rollason T, et al. T-cell responses to human papillomavirus type 16 among women with different grades of cervical neoplasia. Br J Cancer 2005; 93:248-59.
- Nagaraj S, Gupta K, Pisarev V, et al. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med 2007;13:828-35.
- Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004.
- Bais AG, Beckmann I, Lindemans J, Ewing PC, Meijer CJ, Snijders PJ, Helmerhorst TJ. A shift to a peripheral Th2-type cytokine pattern during the carcinogenesis of cervical cancer becomes manifest in CIN III lesions. J Clin Pathol 2005;58:1096-100.
- Kanodia S, Fahey LM, Kast WM. Mechanisms used by human papillomaviruses to escape the host immune response. Curr Cancer Drug Targets 2007; 7:79-89; PMID:17305480.
- Fahey LM, Raff AB, Da Silva DM, Kast WM. Reversal of human papillomavirus-specific T cell immune suppression through TLR agonist treatment of Langerhans cells exposed to human papillomavirus type 16. J Immunol 2009; 82:2919-28.
- Domingos-Pereira S, Decrausaz L, Derre L, et al. Intravaginal TLR agonists increase local vaccine-specific CD8 T cells and human papillomavirus-associated genital-tumor regression in mice. Mucosal Immunol 2013;6:393-404.
- Derre L, Rivals JP, Jandus C, et al. BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination. J Clin Invest 2010; 120:157-67.
- Blank C, Mackensen A. Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol Immunother 2007; 56:739-45.
- Ukpo OC, Thorstad WL, Lewis JS Jr. B7-H1 expression model for immune evasion in human papillomavirus-related oropharyngeal squamous cell carcinoma. Head Neck Pathol 2013;7:113-21.
- Scholten KB, Schreurs MW, Ruizendaal JJ, et al. Preservation and redirection of HPV16E7-specific T cell receptors for immunotherapy of cervical cancer. Clinical Immunology 2005;114:119-29.
- Santin AD, Bellone S, Palmieri M, et al. HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities. Gynecol Oncol 2006;100:469-78.
- Garcia F, Petry KU, Muderspach L, et al. ZYC101a for treatment of high-grade cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 2004;103:317-26.
- Gomez-Gutierrez JG, Elpek KG, Montes de Oca-Luna R, Shirwan H, Sam Zhou H, McMasters KM. Vaccination with an adenoviral vector expressing calreticulin-human papillomavirus 16 E7 fusion protein eradicates E7 expressing established tumors in mice. Cancer Immunol Immunother 2007;56:997-1007.
For any technique error please contact us
American Journal of BioMedicine 2014, Volume 2, Issue 3, pages 137-146
Received 12 February 2014; accepted May 25, 2014, Published July 04, 2014
How to cite this article
Navarro SB, Peiris BM. Human papillomavirus (HPV) vaccine: Gardasil reactions. American Journal of BioMedicine 2014;2(3):137-146.
Case report outline